Kymera Therapeutics, Inc. KYMR
We take great care to ensure that the data presented and summarized in this overview for Kymera Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding KYMR
View all-
Baker Bros. Advisors LP New York, NY6.65MShares$432 Million3.07% of portfolio
-
Avoro Capital Advisors LLC New York, NY6.35MShares$412 Million4.91% of portfolio
-
Bvf Inc San Francisco, CA5.5MShares$357 Million16.85% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.42MShares$352 Million0.0% of portfolio
-
Wellington Management Group LLP Boston, MA5.2MShares$337 Million0.05% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.1MShares$331 Million0.03% of portfolio
-
Atlas Venture Life Science Advisors, LLC4.9MShares$318 Million62.55% of portfolio
-
Black Rock Inc. New York, NY4.16MShares$270 Million0.0% of portfolio
-
Siren, L.L.C. New York, NY3.43MShares$223 Million7.59% of portfolio
-
State Street Corp Boston, MA2.02MShares$131 Million0.0% of portfolio
Latest Institutional Activity in KYMR
Top Purchases
Top Sells
About KYMR
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Insider Transactions at KYMR
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 12
2025
|
Bruce Booth |
SELL
Open market or private sale
|
Indirect |
678
-0.02%
|
$61,698
$91.04 P/Share
|
|
Dec 11
2025
|
Bruce Booth |
SELL
Open market or private sale
|
Indirect |
6,101
-0.14%
|
$555,191
$91.23 P/Share
|
|
Dec 11
2025
|
Baker Bros. Advisors LP |
BUY
Open market or private purchase
|
Indirect |
2,005,813
+19.01%
|
$172,499,918
$86.0 P/Share
|
|
Dec 10
2025
|
Bruce Booth |
SELL
Open market or private sale
|
Indirect |
229,809
-0.99%
|
$20,682,810
$90.73 P/Share
|
|
Dec 08
2025
|
Jared Gollob Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
49,307
-5.9%
|
$4,388,323
$89.77 P/Share
|
|
Dec 08
2025
|
Jared Gollob Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
49,307
+23.64%
|
$246,535
$5.33 P/Share
|
|
Dec 08
2025
|
Nello Mainolfi Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
100,000
-13.15%
|
$8,900,000
$89.17 P/Share
|
|
Dec 08
2025
|
Nello Mainolfi Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
100,000
+11.62%
|
$200,000
$2.08 P/Share
|
|
Dec 08
2025
|
Jeffrey W. Albers |
SELL
Open market or private sale
|
Direct |
5,000
-77.48%
|
$445,000
$89.81 P/Share
|
|
Dec 08
2025
|
Jeffrey W. Albers |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
$70,000
$14.18 P/Share
|
|
Oct 29
2025
|
Nello Mainolfi Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
30,000
-1.46%
|
$1,800,000
$60.73 P/Share
|
|
Oct 29
2025
|
Nello Mainolfi Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+4.16%
|
$60,000
$2.08 P/Share
|
|
Oct 15
2025
|
Jared Gollob Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
59,576
-10.13%
|
$3,634,136
$61.92 P/Share
|
|
Oct 15
2025
|
Jared Gollob Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
51,209
+14.01%
|
$51,209
$1.7 P/Share
|
|
Oct 13
2025
|
Jared Gollob Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,114
-2.56%
|
$186,840
$60.0 P/Share
|
|
Oct 13
2025
|
Jared Gollob Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,473
+0.6%
|
$1,473
$1.7 P/Share
|
|
Oct 13
2025
|
Jeffrey W. Albers |
SELL
Open market or private sale
|
Direct |
5,000
-100.0%
|
$295,000
$59.19 P/Share
|
|
Oct 13
2025
|
Jeffrey W. Albers |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
$50,000
$10.34 P/Share
|
|
Sep 17
2025
|
Bruce N. Jacobs Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
79,220
-25.84%
|
$3,961,000
$50.0 P/Share
|
|
Sep 17
2025
|
Bruce N. Jacobs Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
79,220
+20.53%
|
$158,440
$2.08 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 215K shares |
|---|---|
| Open market or private purchase | 2.98M shares |
| Exercise of conversion of derivative security | 454K shares |
| Open market or private sale | 678K shares |
|---|